

15th RSC-SCI Medicinal Chemistry Symposium

6-9 September 2009
Churchill College, Cambridge, UK

FIRST CIRCULAR



RSC | Advancing the
Chemical Sciences


SCI
where science meets business

Introduction

The organisers cordially invite you to participate in the 15th RSC-SCI Medicinal Chemistry Symposium, a major biennial event in the field of Medicinal Chemistry. This year, reflecting the present climate in pharmaceutical research, the theme of the conference will be **Refining Drug Discovery: Evolution or Revolution!** The scientific programme features lectures on **Enzyme Inhibitors, Ligands for Receptors** and **Ion Channels** plus a **Hot Topic** late breaker session. In addition the meeting has a number of talks addressing key **Enabling Processes and Technologies** for the future of Medicinal Chemistry. There will also be **Poster Sessions** with a number of posters selected for **Short Talks**.

Held at Churchill College Cambridge, UK, this meeting has become synonymous with excellent scientific discussion and enjoyable social discourse. The organisers hope you will accept their invitation to participate in this international symposium.

Scientific Programme

The programme will open at 09.00 on Monday 7 September and close around 16.00 on Wednesday 9 September. The programme will include the following speakers and topics.

Discovery of Potent and Selective Non-steroidal Glucocorticoid Receptor Agonists

David House (GlaxoSmithKline, UK)

MC4 Agonists for the Treatment of Sexual Dysfunction

Mark Lansdell (Pfizer Global R&D, UK)

Next Generation NK-1 Antagonists

Robert DeVita (Merck, USA)

Medicinal Chemistry and Biology of E2007, an Orally-active AMPA Receptor Antagonist, for Neurological Disorders

Koichi Ito (Eisai, Japan)

The Identification of Selective P38 Inhibitors with High Blood Potency Suitable for Clinical Development

Vipul Patel (GlaxoSmithKline, UK)

Progressing Carboxylic Acid Leads as PDE7 Inhibitors

Nigel Swain (Pfizer Global R&D, UK)

Non-nucleoside inhibitors for the Treatment of Hepatitis C Virus Infection

Frank Narjes (Merck Sharp & Dohme, Italy)

Potent, Non-peptidic, Orally-active Renin Inhibitors

Olivier Bezençon (Actelion Pharmaceuticals, Switzerland)

Inhibitors of GSK-3 Kinase for the Treatment of Neurodegenerative Diseases

Juan-Miguel Jimenez (Vertex, UK)

CarboCarrier™: A Novel Technology to Extend the Half-life of Small Proteins and Peptides

Martin de Kort (Schering-Plough, The Netherlands)

Additional Contributions

In order to include papers from a wide spread of medicinal chemistry research, the organisers are holding open slots in the programme for contributed papers. High quality novel approaches or early disclosures will be particularly welcome. Please submit a one-page abstract to the Secretariat by **30 November 2008**.

Poster Session

The poster sessions are an important part of the meeting and contributions from the whole field of medicinal chemistry are invited. Procedures for submission of abstracts will be given in the second circular. A number of conference places are reserved for poster presenters. Those submitting outstanding poster abstracts may be selected to give short talks.

Bursaries

The RSC and the SCI will award a number of student bursaries, to support costs associated with registration and accommodation. Further details will be given in the second circular.

Application and Accommodation

Attendance is limited to around 280 delegates and the meeting is usually fully-subscribed. En-suite accommodation will be available in Churchill College and in New Hall. Standard rooms will also be available if required. Details, costs and application forms will be included in the second circular which is expected to be available in February. Please see below to request a copy.

Exhibition

There are opportunities for companies to take part in the exhibition associated with the meeting. Further information can be obtained from the Secretariat in January.

Organising Committee

The Symposium is organised jointly by the RSC Biological and Medicinal Chemistry Sector and the SCI Fine Chemicals Group.

David Witty, GlaxoSmithKline, Chair
Urs Baettig, Novartis, Secretary
Phil Jones, Schering-Plough, Treasurer
Alan Stobie, Pfizer GRD
Chris Swain, Cambridge MedChem Consulting
Steve Swallow, AstraZeneca
Andrew Williams, Eli Lilly

Further Information and Secretariat

The second circular and application form will be available in **February 2009** and will be sent to those who have contacted the Secretariat to request a copy.

Please send your name, address and email address to:

Elaine Wellingham, Conference Secretariat
15th RSC-SCI Medicinal Chemistry Symposium

Email: esw@confsec.co.uk
Tel and Fax: +44 (0)1275 853311
www.confsec.co.uk